Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
AssigneeCellectar, Inc.
InventorsJamey P. Weichert, Marc Longino, Anatoly Pinchuk
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer, Hepatocellular carcinoma, Retinoblastoma, Cervical cancer, Glioma, Breast cancer and Pancreatic cancer in subject using phospholipid ether analogs.
Claims32
1-20. (canceled)
A method, comprising:
- determining cancer in a subject to which 124I-labeled 18-(p-iodophenyl)octadecyl phosphocholine has been administered by determining 124I radioactivity in the subject.
A method of differentiating inflammation, adenoma, hyperplasia, or neoplasia in a subject, the method comprising:
- providing a subject to which 124I-labeled 18-(p-iodophenyl)octadecyl phosphocholine has been administered;
- and
- determining whether the subject has inflammation, adenoma, hyperplasia, or neoplasia by determining 124I radioactivity in the subject.
A method for determining radiation- and chemo-insensitive cancer or cancer metastasis, comprising:
- providing a subject to which 124I-labeled 18-(p-iodophenyl)octadecyl phosphocholine has been administered;
- and
- determining whether the subject has radiation- and chemo-insensitive cancer or cancer metastasis by determining 124I radioactivity in the subject.
The method of claim 48, comprising determining 124I-radioactivity using PET scanning.
Dependencies are inferred from the claim text.